19 results on '"Kumai, Takumi"'
Search Results
2. Effects of Molecular Orientation of a Fullerene Derivative at the Donor/Acceptor Interface on the Device Performance of Organic Photovoltaics.
3. Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma
4. Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma
5. Effects of Molecular Orientation of a Fullerene Derivative at the Donor/Acceptor Interface on the Device Performance of Organic Photovoltaics
6. Thyroid metastasis from cervical carcinoma
7. Treatment outcomes of alternating chemoradiotherapy for nasopharyngeal carcinoma: a single-center safety and efficacy study
8. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
9. Spontaneous Pneumomediastinum: Unusual Cause of Sore Throat.
10. IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer
11. Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC
12. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
13. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma
14. Correction to Effects of Molecular Orientation of a Fullerene Derivative at the Donor/Acceptor Interface on the Device Performance of Organic Photovoltaics.
15. Correction to Effects of Molecular Orientation of a Fullerene Derivative at the Donor/Acceptor Interface on the Device Performance of Organic Photovoltaics
16. H3K4me3 mediates the NF-κB p50 homodimer binding to the pdcd1promoter to activate PD-1 transcription in T cells
17. Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma
18. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy
19. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.